Sanofi-Aventis, which is developing teriflunomide, funded TEMSO. Dr. Miller, Dr. Wolinsky, and many of their associates in the study disclosed relationships with Sanofi-Aventis and with numerous other companies that make therapies for multiple sclerosis. Three coinvestigators were employees of Sanofi-Aventis.
The challenge of the oral drugs will come from a lack of guidance on which drug or drugs to prioritize in treatment.
Source DR. KITA
Both teriflunomide doses reduced the annualized relapse rate by approximately 31%, compared with placebo.
Source DR. MILLER